At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 496 enrolled

Drug / intervention

MK0954, /Duration of Treatment : 5 Years +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00338260

NCT00338260Phase 3Completed

Compare CT.gov

A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

Organon and Co·interventional·Posted Jun 20, 2006·Updated Feb 15, 2022

In Brief

A Phase 3 clinical trial evaluating MK0954, /Duration of Treatment : 5 Years and Comparator : atenolol /Duration of Treatment : 5 Years for Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart). Completed, enrolled 496 participants.

Detailed Summary

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

Countries--

Collaborators--

Timeline

Phase 3CompletedFinished

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJun 1995

Primary CompletionSep 2001

Study CompletionNov 2001

First PostedJun 2006

TodayJul 2026

First PostedJun 20, 2006

Enrollment StartJun 1, 1995

Primary CompletionSep 1, 2001

Study CompletionNov 1, 2001

TodayJul 2, 2026

Enrollment to primary: 6.3 yearsPosted 20.0 years ago

Interventions

MK0954, /Duration of Treatment : 5 Yearsdrug

Comparator : atenolol /Duration of Treatment : 5 Yearsdrug